GlassScriptPhysician profile
Ram S Garg
NPI 1164402442
$110,911.05
in general payments reported to CMS, 2019-2025
56 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $23K · 2021: $20K · 2022: $28K · 2023: $12K · 2024: $3,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,740 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,175 · Honoraria: $2,275 · Education: $34.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,740.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,175.00 |
| Honoraria | $2,275.00 |
| Education | $34.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26,802.77 | 2021-2024 | |
| Eisai INC. | $25,157.12 | 2019-2024 | |
| Genzyme Corporation | $11,901.85 | 2019-2023 | |
| Allergan, INC. | $11,259.57 | 2019-2021 | |
| Sk Life Science, INC. | $9,161.21 | 2020-2024 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $6,890.08 | 2019-2024 | Austedo Xr, Uzedy, Ajovy |
| Biogen, INC. | $2,579.29 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Catalyst Pharmaceuticals, INC. | $2,544.65 | 2021-2024 | Fycompa |
| Ucb, INC. | $2,116.48 | 2019-2024 | Briviact, Nayzilam, Fintepla |
| Novartis Pharmaceuticals Corporation | $2,017.61 | 2019-2024 | |
| Emd Serono, INC. | $1,030.91 | 2019-2024 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $1,012.59 | 2019-2023 | Oxtellar Xr |
| Neurocrine Biosciences, INC. | $956.06 | 2019-2024 | Ingrezza, Ongentys |
| Neurelis, INC. | $484.36 | 2021-2024 | Valtoco |
| Sunovion Pharmaceuticals INC. | $464.06 | 2019-2022 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $460.08 | 2019-2023 | Apokyn |
| Amgen INC. | $455.16 | 2019-2024 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $442.45 | 2019-2024 | Trintellix |
| Celgene Corporation | $407.93 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $403.66 | 2020-2024 | Emgality, Reyvow, Amyvid |
| Jazz Pharmaceuticals INC. | $351.28 | 2019-2024 | |
| Adamas Pharmaceuticals, INC. | $340.65 | 2019-2021 | |
| Argenx US, INC. | $275.22 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Lundbeck LLC | $237.47 | 2019-2024 | Vyepti, Rexulti |
| Pfizer INC. | $235.68 | 2019-2024 | |
| Genentech USA, INC. | $235.56 | 2019-2024 | Ocrevus, Enspryng |
| Kyowa Kirin, INC. | $229.09 | 2020-2024 | Nourianz |
| Amneal Pharmaceuticals LLC | $194.18 | 2020-2024 | Ongentys 50mg Capsules 30, Rytary |
| Tanabe Pharma America, INC. | $184.23 | 2019-2024 | |
| Corium, LLC | $179.62 | 2022-2023 | Adlarity |
| Axsome Therapeutics, INC. | $178.39 | 2023-2024 | Auvelity |
| Horizon Therapeutics Plc | $171.09 | 2022-2023 | Uplizna |
| Avanir Pharmaceuticals, INC. | $143.68 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $135.68 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.12 | 2021-2024 | Caplyta |
| Sumitomo Pharma America, INC. | $119.86 | 2023-2024 | Aptiom |
| Alexion Pharmaceuticals, INC. | $117.48 | 2019-2024 | Soliris, Ultomiris |
| Aquestive Therapeutics, INC. | $115.69 | 2019-2022 | |
| Harmony Biosciences LLC | $79.99 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $79.90 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $76.19 | 2021-2024 | |
| Greenwich Biosciences, INC. | $64.02 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $63.53 | 2020-2021 | |
| Livanova USA, INC. | $62.38 | 2020-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Zogenix INC. | $60.62 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $51.94 | 2022-2023 | Rexulti |
| Acorda Therapeutics, INC | $46.86 | 2019 | |
| Acadia Pharmaceuticals INC | $38.44 | 2020-2023 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $38.09 | 2020-2021 | |
| Owp Pharmaceuticals, INC. | $35.22 | 2023 | Subvenite, Lamotrigine |
| Impel Pharmaceuticals INC. | $24.36 | 2022 | |
| Tg Therapeutics, INC. | $22.27 | 2023 | |
| Banner Life Sciences, LLC | $18.82 | 2022 | |
| Vanda Pharmaceuticals INC. | $15.67 | 2019 | |
| Merck Sharp & Dohme LLC | $12.06 | 2019 | |
| Sanofi-Aventis U.S. LLC | $2.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ram Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.